BRIEF published on 08/12/2025 at 07:35, 1 year ago Dermapharm Holding SE poursuit sa croissance au deuxième trimestre 2025 Prévisions De Revenus Croissance De L'EBITDA Produits Pharmaceutiques De Marque Dermapharm Performances Du Deuxième Trimestre 2025
BRIEF published on 08/12/2025 at 07:35, 1 year ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 1 year ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 1 year 2 months ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
BRIEF published on 06/26/2025 at 17:48, 1 year 2 months ago Dermapharm Holding SE approuve un dividende de 0,90 € par action Dividende Durabilité Assemblée Générale Annuelle Perspectives Financières Dermapharm
PRESS RELEASE published on 06/26/2025 at 17:43, 1 year 2 months ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share Dermapharm Holding SE's Annual General Meeting approves divident distribution of EUR 0.90 per share for 2024, confirms 2025 outlook and ratifies Board actions Annual General Meeting Financial Year 2024 Dividend Distribution Dermapharm Holding SE EUR 0.90 Per Share
BRIEF published on 05/15/2025 at 07:35, 1 year 3 months ago Dermapharm Holding SE répond aux attentes du premier trimestre 2025 et renforce ses prévisions pour l'ensemble de l'année Croissance Des Revenus Baisse De L'EBITDA Orientation Pour L'année Entière Produits Pharmaceutiques De Marque Dermapharm T1 2025
BRIEF published on 05/15/2025 at 07:35, 1 year 3 months ago Dermapharm Holding SE Meets Q1 2025 Expectations, Reinforces Full-Year Forecast Revenue Growth Full-year Guidance EBITDA Decline Branded Pharmaceuticals Dermapharm Q1 2025
PRESS RELEASE published on 05/15/2025 at 07:30, 1 year 3 months ago Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance Dermapharm Holding SE reports Q1 2025 results in line with projections, confirming full-year guidance. Revenue increases by 1.2% year-on-year to EUR 302.4 million Adjusted EBITDA Revenue Growth Dermapharm Holding SE Full-year Guidance Q1 2025 Results
BRIEF published on 03/28/2025 at 07:35, 1 year 5 months ago Les résultats financiers de Dermapharm en 2024 dépassent les attentes Augmentation Des Revenus Croissance De L'EBITDA Résultats Financiers 2024 Produits Pharmaceutiques De Marque Dermapharm
Published on 08/28/2026 at 08:05, 4 hours 54 minutes ago Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 4 hours 54 minutes ago Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 4 hours 59 minutes ago Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Published on 08/28/2026 at 04:30, 8 hours 29 minutes ago Snipp Interactive Reports Q2 2026 Financial Results; Returns to Positive EBITDA on Highest Quarterly Revenue in Five Quarters
Published on 08/27/2026 at 23:05, 13 hours 54 minutes ago Galway Metals Announces Filing of NI 43-101 Technical Report for Updated Clarence Stream Mineral Resource Estimate
Published on 08/28/2026 at 12:43, 15 minutes ago Annual General Meeting of MPC Capital AG approves change of name to MPC Oceanic Group AG
Published on 08/28/2026 at 12:43, 16 minutes ago IVU and Hellenic Train collaborate to enhance Rail Mobility in Greece
Published on 08/28/2026 at 11:15, 1 hour 43 minutes ago Redcare Pharmacy announces Managing Board succession: Peter Schmid von Linstow to succeed Olaf Heinrich as part of a planned leadership transition.
Published on 08/28/2026 at 11:12, 1 hour 46 minutes ago EQS-Adhoc: Redcare Pharmacy N.V.: Change in the Managing Board; Peter Schmid von Linstow to become Chief Executive Officer.
Published on 08/26/2026 at 18:02, 1 day 18 hours ago Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:02, 1 day 18 hours ago Altareit : Communiqué de presse d’Altarea relatif au dossier Primonial
Published on 08/26/2026 at 18:00, 1 day 18 hours ago Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
